Skip to main content
OpenTrials
Completed

NCT Number: NCT02950428

ACURATE Neo™ TA Delivery System in Patient With Severe Aortic Stenosis

The purpose of this investigation is to collect data pertaining to the safety and performance of the ACURATE neo (TM) Aortic Bioprosthesis as implanted with the ACURATE neo (TM) TA Transapical Delivery System. This device is intended for treatment of subjects with severe aortic stenosis (AS) who have high risk for conventional aortic valve replacement (AVR) surgery. The ACURATE neo (TM) Aortic Bioprosthesis is intended for use via minimally-invasive transapical implantation in a well-defined population.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Kerckhoff-Klinik, Bad Nauheim, Germany

Loading trial locations.

About this study

This is a single arm, prospective, multicenter non randomised and open trial of the treatment of patients with severe aortic stenosis where conventional aortic valve replacement (AVR) via open heart surgery is considered to be high risk. All patients will be followed up to 5 years after the intervention.

The primary objective is to evaluate the safety and performance of the study device in patients presenting with severe aortic stenosis considered to be high risk for surgery Secondary objective is to evaluate adverse events and study device performance.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject must be at least 18 years old
  • Severe aortic stenosis defined as:
  • Mean aortic gradient > 40 mmHg or
  • Peak jet velocity > 4.0 m/s or
  • Aortic valve area of < 0.8 cm2
  • High risk patient determined by a multidisciplinary heart team consensus (cardiologist and cardiac surgeon) that patient is not a surgical candidate for conventional AVR due to risk factors such as STS Score (8% or higher) or other co-morbid conditions unrelated to aortic stenosis such as severe chronic obstructive pulmonary disease (COPD), chest deformities and irradiated mediastinum
  • NYHA Functional Class > II
  • Multidisciplinary heart team (cardiologist and cardiac surgeon) consensus that the transapical approach is the most suitable access route for TAVI due to the presence of the following anatomic conditions:
  • porcelain aorta or
  • severely calcified or highly tortuous peripheral vasculature not appropriate for transfemoral transcatheter aortic valve implantation or
  • vessels too small for retrograde approach or
  • other anatomical conditions making transapical approach more suitable
  • Aortic annulus diameter from ≥ 21mm up to ≤ 27mm by CT or TEE
  • Patient willing to participate in the study and provides signed informed consent

Exclusion criteria

  • Congenital unicuspid or bicuspid aortic valve or non-calcified
  • Extreme eccentricity of calcification
  • Severe mitral regurgitation (> Grade 3)
  • Pre-existing prosthetic heart valve in any position and / or prosthetic ring
  • LV apex is not accessible via transapical access due to severe chest deformity
  • Previous surgery of the LV using a patch, such as the Dor procedure
  • Presence of apical LV thrombus
  • Calcified pericardium
  • Septal hypertrophy unacceptable for transapical procedure
  • Transesophageal echocardiogram (TEE) is contraindicated
  • ECHO evidence of intracardiac mass, thrombus, or vegetation
  • LVEF < 20% by ECHO
  • Need for emergency intervention for any reason within 30 Days of scheduled procedure
  • Any percutaneous intervention, except for balloon valvuloplasty (BAV) within 1 month prior to implant procedure
  • Untreated clinically significant coronary artery disease requiring revascularization within 30 days before or after the study procedure
  • Acute myocardial infarction within 1 month prior to implant procedure
  • Previous TIA or stroke within 6 months prior to implant procedure
  • Active gastrointestinal (GI) bleeding within 3 months prior to implant procedure
  • Scheduled surgical or percutaneous procedure to be performed prior to 30 day visit
  • History of bleeding diathesis, coagulopathy, refusal of blood transfusions or severe anemia (Hb<8 g/dL)
  • Systolic pressure <80mmHg, cardiogenic shock, need for inotropic support or IABP
  • Primary hypertrophic obstructive cardiomyopathy (HOCM)
  • Active infection or endocarditis
  • Hepatic failure (> Child B)
  • Chronic renal dysfunction with serum creatinine > 3.0 mg/dL or renal dialysis
  • Neurological disease severely affecting ambulation, daily functioning, or dementia
  • Life expectancy < 12 months due to non-cardiac co-morbid conditions
  • Intolerance to aspirin, clopidogrel, contrast media, or porcine tissue and allergy to nickel
  • Pregnant or breast-feeding women
  • For other severe illnesses of the patient (e.g. active carcinoma), the investigator shall decide on an individual basis whether the patient is not to be included in the study
  • Currently participating in an investigational drug or another device study

Treatment and study plan

ACURATE neo™TA Delivery System

Device

ACURATE neo™ Aortic Bioprosthesis and ACURATE neo™TA Transapical Delivery System on patients with severe aortic stenosis where conventional aortic valve replacement (AVR) via open-heart surgery is considered to be high risk

Primary outcomes

  1. Primary Safety: freedom from all-cause mortality

    Time frame: 6 months post procedure

    freedom from all-cause mortality

  2. Primary Device Performance:Procedure success in absence of MACCE

    Time frame: 30 days post procedure

    Procedure success in absence of MACCE

Secondary outcomes

  1. Rate of clinical endpoints according to the Valve Academic Research Consortium (VARC 2) guidelines

    Time frame: 30 Days and month 12

    VARC 2 guidelines include different safety and efficacy endpoints like mortality, MI, stroke, etc.

  2. Incidence of all cause mortality at 30 Days and 12 Months

    Time frame: 30 days and 12 months

    Incidence of all cause mortality at 30 Days and 12 Months

  3. Freedom from MACCE at 30 Days, 6 Months and 12 Months

    Time frame: 30 Days, 6 Months and 12 Months

    Freedom from MACCE at 30 Days, 6 Months and 12 Months

  4. Number of patients who have a Procedural success defined by a combination of criteria

    Time frame: procedure

    Procedural success defined as ACURATE neo™ at intended location with

  5. Rate of device success

    Time frame: 7 days/ Discharge, 30 Days, 6 Months and at 12 Months

    Rate of device success

  6. NYHA Functional Classification improvement

    Time frame: 30 Days, 6 Month and at 12 Months

    NYHA Functional Classification improvement

  7. Echocardiographic assessment of valve performance (at 7 Days or Discharge, 30 Days, 6 Months, 12 Months) using a combination of measures

    Time frame: 7 Days or Discharge, 30 Days, 6 Months, 12 Months

    Echocardiographic assessment of valve performance (at 7 Days or Discharge, 30 Days, 6 Months, 12 Months) using a combination of measures

Sponsors and collaborators

Lead sponsor

Symetis SA

Industry

Registry information

Official study title

ACURATE Neo™ Aortic Bioprosthesis for Implantation Using the ACURATE Neo™ TA Transapical Delivery System in Patients With Severe Aortic Stenosis

Important dates

Study start
2015
Primary completion
2017
Study completion
2021
First posted
Nov 1, 2016
Registry last updated
Feb 23, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.